Novel therapeutic options for osteoporosis

Current Opinion in Rheumatology

Volumn 14, Issue 4, 2002, Pages 447-452

  Biskobing, Diane M ^a   Novy, Angela M ^a   Downs Jr , Robert ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARZOXIFENE; BAZEDOXIFENE; BISPHOSPHONIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBANDRONIC ACID; ISOFLAVONE; OSTEOPROTEGERIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TIBOLONE; ZOLEDRONIC ACID; CELL RECEPTOR; GLYCOPROTEIN; IMIDAZOLE DERIVATIVE; PIPERIDINE DERIVATIVE; PREGNANE DERIVATIVE; THIOPHENE DERIVATIVE; TNFRSF11B PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RECEPTOR;

BONE DENSITY; DRUG EFFICACY; DRUG MECHANISM; HUMAN; NONHUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; ANIMAL; CONTROLLED CLINICAL TRIAL; DISEASE MODEL; EVIDENCE BASED MEDICINE; PATHOLOGIC FRACTURE;

ANIMAL; CONTROLLED CLINICAL TRIALS; DIPHOSPHONATES; DISEASE MODELS, ANIMAL; EVIDENCE-BASED MEDICINE; FRACTURES, SPONTANEOUS; GLYCOPROTEINS; HUMAN; IMIDAZOLES; NORPREGNENES; OSTEOPOROSIS; PIPERIDINES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SELECTIVE ESTROGEN RECEPTOR MODULATORS; THIOPHENES; ANIMALS; HUMANS; OSTEOPROTEGERIN; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 0035985919     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200207000-00020     Document Type: Review

References (44)

1. LY353381 HCL: A novel raloxifene analog with improved SERM potency and efficacy in vivo
2. Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer
3. TSE-424, a novel tissue selective estrogen, reduces biochemical indices of bone metabolism in a dose related fashion
4. Efficacy of levormeloxifene in the prevention of postmenopausal bone loss and on the lipid profile compared with low dose hormone replacement therapy
5. Effect of selective estrogen receptor modulators on reproductive tissues other than endometrium
6. Tibolone for postmenopausal women: Systematic review of randomized trials
7. Prevention of bone loss with tibolone in postmenopausal women: Results of two randomized, double-blind, placebo-controlled, dose-finding studies
8. Bone density changes during two years treatment with tibolone or conjugated estrogens and norgestrel, compared with untreated controls in postmenopausal women
9. Effects of 8 years of treatment with tibolone 2.5 mg daily on postmenopausal bone loss
10. A randomized study of tibolone on bone mineral density in osteoporotic postmenopausal women with previous fractures
11. A double-blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms
12. Absent correlation between vaginal bleeding and estradiol levels or endometrial morphology during tibolone use in early postmenopausal women
13. Biochemical targets of the isoflavone genistein in tumor cell lines
14. Overview of naturally occurring endocrine-active substances in the human diet in relation to human health
15. Soy intake related to menopausal symptoms, serum lipids, and bone mineral density in postmenopausal Japanese women
16. High dietary phytoestrogen intake is associated with higher bone mineral density in postmenopausal but not premenopausal women
17. Ipriflavone prevents radial bone loss in postmenopausal women with low bone mass over 2 years
18. Effect of ipriflavone - A synthetic derivative of natural isoflavones - On bone mass loss in the early years after menopause
19. The effect of isoflavones extracted from red clover (Rimostil) on lipid and bone metabolism
20. Ipriflavone in the treatment of postmenopausal osteoporosis
21. The effect on bone mass and bone markers of different doses of ibandronate: A new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: A 1-year, randomized, double-blind, placebo-controlled dose-finding study
22. Ibandronate: A comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis
23. Intravenous zoledronic acid in postmenopausal women with low bone mineral density
24. Tri-monthly intravenous injections of ibandronate (2 mg) for treatment of postmenopausal osteoporosis
25. Combination therapy with ibandronate and calcitriol is effective in patients following liver transplantation
26. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density
27. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis
28. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation
29. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL
30. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification
31. The effect of a single dose of osteoprotegerin in postmenopausal women
32. Stimulation of bone formation in vitro and in rodents by statins
33. Simvastatin increases serum osteocalcin concentration in patients treated for hypercholesterolemia
34. HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients
35. Oral statins and increased bone mineral density in postmenopausal women
36. Statin use and bone mineral density (BMD) in older women: The Women's Health Initiative Observational Study (WHF-OS)
37. Inhibitors of hydroxymethylglutarylcoenzyme A reductase and risk of fracture among older women
38. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients
39. HMG CoA reductase inhibitors and the risk of fractures
40. Use of statins and risk of fracture
41. Effect of pravastatin on frequency of fracture in the LIPID study: Secondary analysis of a randomised controlled trial
42. Does statin use reduce risk of fracture in postmenopausal women? Results from the Women's Health Initiative Observational Study (WHI-OS)
43. Statin use and fracture: A meta-analysis of 8 observational studies
44. Statins and their potential for osteoporosis